Tumor Suppressing Viruses, Genes, and Drugs Innovative Cancer Therapy Approaches

Name: Tumor Suppressing Viruses, Genes, and Drugs Innovative Cancer Therapy Approaches
Price: 117.95 USD
Availability: InStock
ISBN: 9780124762497

ISBN-10: 0124762492

ISBN-13: 9780124762497

Edition: 2002

Authors: Hiroshi Maruta

List price: $155.00

30 day, 100% satisfaction guarantee!

Marketplace

1 new & used from $117.95

what's this?

Rush Rewards U
Members Receive:

You have reached 400 XP and carrot coins. That is the daily max!

Description:

There has been increased focus on alternative treatments for cancer. This text presents cancer therapeutics being used or developed as a result of our knowledge about oncogenes, tumour, tumour suppressor genes and viral and non-viral replication.

Book details

List price: $155.00
Copyright year: 2002
Publisher: Elsevier Science & Technology
Publication date: 12/3/2001
Binding: Hardcover
Pages: 425
Size: 6.00" wide x 9.00" long x 1.00" tall
Weight: 1.606
Language: English



Contributors


Preface



Oncolytic Viruses: Virotherapy for Cancer




Introduction



Attributes of Replication-Selective Viruses for Cancer Treatment



Approaches to Optimizing Tumor-Selective Viral Replication



Adenoviruses



Poliovirus



Vesicular Stomatitis Virus



Reovirus



Bacteria



Vaccinia Virus



Herpesvirus



Clinical Trial Results with Replication-Competent Adenoviruses in Cancer Patients



Results from Clinical Trials with dl1520 (Onyx-015, or CI-1042)



Future Directions: Approaches to Improving the Efficacy of Replication-Selective Viral Agents



Summary


References



Reovirus Therapy of Ras-Associated Cancers




Introduction



Reovirus Oncolysis



Concluding Remarks


References



Oncolytic Herpes Simplex Virus (G207) Therapy: From Basic to Clinical




Introduction



Preclinical Studies of G207



G207 Clinical Trial



Conclusions


References



p53 and Its Targets




Introduction



Activation of p53



Downstream Mediators of p53


References



Prospects for Tumor Suppressor Gene Therapy: RB as an Example




Introduction



Functions of RB



Successes with RB Gene Therapy



Perspectives


References



CDK Inhibitors: Genes and Drugs




Introduction



G1 Regulation



p16[superscript INK4a] and the Rb Pathway



p19[superscript ARF] and p53 Pathway



p27 and Human Cancer



Conclusions and Future Perspectives


References



CDK Inhibitors: Small Molecular Weight Compounds




Introduction



Cylin-Dependent Kinases, the Cell Cycle, and Cancer



Cyclin-Dependent Kinase Inhibitors, a Large Variety of Structures



Cyclin-Dependent Kinase Inhibitors, All Competing with ATP



Cyclin-Dependent Kinase Inhibitors, the Selectivity Problem



Cyclin-Dependent Kinase Inhibitors, Cellular Effects



Cyclin-Dependent Kinase Inhibitors, Antitumor Activity



Conclusion


References



NF1 and Other RAS-Binding Peptides




RAS Molecules: Normal versus Oncogenic Mutants



Super GAP?



RAS-Binding Fragment of NF1



c-RAF-1



PI-3 Kinase



Ral GDS


References



Cytoskeletal Tumor Suppressor Genes




Introduction (Historical Background)



Type I Cytoskeletal Tumor Suppressors



Type II Cytoskeletal Tumor Suppressors


References



TGF-[beta] Signaling and Carcinogenesis




Introduction



Dual Role of TGF-[beta] in Carcinogenesis



TGF-[beta] Superfamily Signaling



Perturbation of TGF-[beta] Signaling in Cancer Cells



Perspectives


References



DAN Gene




Introduction



Cloning of DAN cDNA



Transfection of DAN



Role of DAN in Neuroblastomas



Structural Features of the DAN Protein



Genomic Structure of DAN



DAN Family


References



Design of Hammerhead Ribozymes and Allosterically Controllable Maxizymes for Cancer Gene Therapy




Introduction



Ribozyme Expression System in Cells



Design of the tRNA[superscript Val]-Driven Ribozyme That Is Transcribed by pol III



Design of Allosterically Controlled Maxizymes



Conclusion


References



Inhibitors of Angiogenesis




Introduction--Angiogenesis



Angiogenesis Inhibitors



Future Directions


References



Geranylgeranylated RhoB Mediates the Apoptotic and Antineoplastic Effects of Farnesyltransferase Inhibitors: New Insights into Cancer Cell Suicide




Introduction



Do Farnesyltransferase Inhibitors Target a Unique Aspect of Neoplastic Pathophysiology?



Ras Is Not a Crucial Target of Farnesyltransferase Inhibitors



RhoB Is a Crucial Target of Farnesyltransferase Inhibitors



Farnesyltransferase Inhibitors Act through a Gain of Function Mechanism Involving RhoB-GG



RhoB-GG Is Required to Mediate Apoptosis by Farnesyltransferase Inhibitors



RhoB-GG and the Antiangiogenic Properties of Farnesyltransferase Inhibitors



Clinical Implications



Summary


References



RAS Binding Compounds




Introduction



Ras Cycle and Ras-Raf Signaling Pathway



The Structure of Ras Proteins



Drug Target Sites of Ras



Conclusions and Outlook


References



Actin-Binding Drugs: MKT-077 and Chaetoglobosin K (CK)




Introduction



MKT-077: F-Actin Bundler



Chaetoglobosin K: F-Actin Capper


References



Tyr Kinase Inhibitors as Potential Anticancer Agents: EGF Receptor and ABL Kinases




Introduction



Tyr Kinase Inhibitors



Chronic Myelogenous Leukemia



Epidermal Growth Factor Receptor



Antagonists of the Epidermal Growth Factor Receptor Extracellular Domain



Chemical Inhibitors of the Kinase Domain of the Epidermal Growth Factor Receptor



Epidermal Growth Factor Receptor Antagonists or Inhibitors Act Synergistically to Kill Tumor Cells



The Effects of Abl Inhibitors on Leukemia


References



Antagonists of Rho Family GTPases: Blocking PAKs, ACKs, and Rock




Rho Family GTPases (Rho, Rac, and CDC42)



Blocking PAKs



Blocking CDC42 Pathways (ACKs and N-WASP)



Blocking Rho Pathways



Rac-Specific Inhibitors?


References



Integrin Antagonists as Cancer Therapeutics




Introduction



Signaling Pathways Activated by Integrins



Role of Integrins in Neoplastic Transformation



Role of Integrins in Tumor-Induced Angiogenesis



Integrin Antagonists as Antiangiogenesis Agents



Conclusions and Future Perspectives


References



Functional Rescue of Mutant p53 as a Strategy to Combat Cancer




Introduction



Multiple Pathways of p53-Induced Apoptosis



Regulation of p53 Activity



Approaches toward Reactivation of Mutant p53



Implications for Tumor Therapy and Future Perspectives


References


Index